Zobrazeno 1 - 10
of 63
pro vyhledávání: ''
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 33:e584-e589
This retrospective study was conducted to explore the effects of anlotinib as first-line treatment for patients with advanced lung adenocarcinoma. We retrospectively reviewed medical records of 60 patients with advanced lung adenocarcinoma, admitted
Autor:
Tianwen Gao, Yanhong Zhao, Lei Wang, Tao Zhao, Weinan Guo, Guannan Zhu, Weigang Zhang, Qiong Shi, Lin Liu, Chunying Li, Yu Liu, Jianhong Zhao
Publikováno v:
Anti-Cancer Drugs. 32:1105-1110
Objectives Recombinant human interferon-α1b (IFN-α1b) is the first genetic engineered drug of China and is approved for cancer treatment by Chinese Food and Drug Administration. Although recombinant IFN-α1b is biologically and therapeutically acti
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many
Publikováno v:
Anti-Cancer Drugs. 31:959-965
After the failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, some non-small cell lung cancer patients desire to receive switching with another EGFR-TKI (TKI-switching), although cytotoxic chemotherapy
Publikováno v:
Anti-Cancer Drugs. 31:973-978
Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast can
Autor:
Hideki Marushima, Hiroyuki Kimura, Haruhiko Nakamura, Hisashi Saji, Naoki Furuya, Hiroki Sakai, Kojima Koji, Tomoyuki Miyazawa
Publikováno v:
Anti-Cancer Drugs
The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, a
Autor:
Terence Chi Chun Tam, James Chung-Man Ho, Macy Mei Sze Lui, Mary S.M. Ip, David C.L. Lam, Wang Chun Kwok
Publikováno v:
Anti-Cancer Drugs. 30:1048-1051
As a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib was approved by the US Food and Drug Administration for treatment of advanced non-small cell carcinoma with sensitizing EGFR mutations. Gefitinib is known to
Publikováno v:
Anti-cancer drugs. 32(10)
Publikováno v:
Anti-cancer drugs. 33(1)
Palliative chemotherapy can improve outcomes in most patients with advanced soft tissue sarcoma (STS), but the treatment of elderly patients remains a challenge because of older age, comorbidities and poor performance status. This study retrospective